All Industry Workshops take place on Wednesday, April 22nd from 11:30am-12:30pm at the George R. Brown Convention Center. Rooms are listed below, and lunch will be provided.

These Industry Workshops provide an opportunity for AMCP corporate members (commercial organizations) to showcase their latest drug therapies, technologies, and a wealth of products and services affecting professionals  working in managed care pharmacy. Seating is limited and we encourage attendees to come early, as seating is on a first-come, first-seated basis. Material presented in workshops may be promotional and may concentrate on a specific product, service or therapeutic area. Therefore, these presentations are considered promotional and do not offer continuing education credit.

Wednesday, April 22

A Treatment Option for a Broad Range of Patients With Spinal Muscular Atrophy

Hosted by Biogen
11:30am – 12:30pm / Room 381

Description: Presented by a leading healthcare professional with expertise treating spinal muscular atrophy, on behalf of Biogen Spinal muscular atrophy (SMA), a rare, progressive, neuromuscular disease, is a spectrum genetic disorder that affects a wide range of patients, including infants, children, and adults. Primarily diagnosed in infants and children, SMA is a leading cause of infant mortality. Early identification of the disease is important to determine an effective care and treatment plan. This session will provide an overview of the disease and highlight the potential benefits of therapeutic intervention on the survival and motor function for a broad range of patients with SMA. This program is open only to representatives of payers, formulary committees, or other similar entities who have responsibility for the selection of drugs for coverage or reimbursement.
SPZ-US-3248      02/20

Speaker: Diana Patricia Castro, MD

SPRAVATO® for Treatment Resistant Depression

Hosted by Janssen Pharmaceuticals, Inc
11:30am – 12:30pm / Room 382

Description: Expert-led discussion regarding the implementation of SPRAVATO® treatment for patients with Treatment-Resistant Depression

Speaker: TBD

State of the Science in Oncology: The Era of Antibody Drug Conjugates

Hosted by Seattle Genetics, Inc.
11:30am – 12:30pm / Room
361 ABC 

Description: In this wave of innovation in Oncology, antibody-drug conjugates (ADCs) continue to improve outcomes for patients with cancer. With the proven ADC technology platform leading the way of cutting-edge cancer research, improvements to the science and technology have led to increased development and approval of newer ADCs. Scientific advancements have also led to the potential of combining ADCs with treatments such as immunotherapy to further improve outcomes. This session will provide an overview of the evolving Oncology landscape, discuss the state of ADC technology, and highlight FDA-approved and novel ADCs on the horizon. Following the presentation, a panel comprised of diverse key decision makers in the US healthcare system will discuss their perspectives of ADCs and the value of targeted therapies in Oncology.

Moderator: Cindy McDonald-Everett, Vice President, Global Value, Access, and Pricing, Seattle Genetics

Panelists: Nilanjan Ghosh, MD, PhD, Chief, Lymphoma Division & Associate Director, Clinical Trials Levine Cancer Institute, Atrium Health, Clinical Associate, Professor of Medicine, UNC-Chapel Hill School of Medicine

Jeremy Whalen, PharmD, BCOP, Specialty Clinical Program, Director, Oncology, Prime Therapeutics

Timothy Chiu, PharmD, BCPS, Pharmacist Evidence Analyst & Strategist – Hematology/Oncology and Palliative Care, Drug Intelligence and Strategy, Kaiser Permanente